Pappas Capital

We are excited to share that an article discussing the treatment of conjunctival melanoma cell lines with bel-sar was recently published in IOVS, an Association for Research in Vision and Ophthalmology (ARVO) Journal. A special thanks to Dr. Martine Jager for her partnership on the article. A link to the full article can be found here: bit.ly/3YJVyJk

Congratulations to Pappas Capital portfolio company EarthOptics on the successful completion of its $24 million financing. https://lnkd.in/gmz5RCta

Yesterday at #AASLD2024, we showcased exciting new data supporting our mission to develop a functional cure for chronic Hepatitis B Virus infection (#HBV), using Tune-401 – an epi-silencing drug now approved for clinical trial in New Zealand. This progress is a testament to the potential of epi-editing to deliver lasting impacts in common and chronic diseases. #LiverDisease #HepatitisBCure #EpigenomeEditing LEARN MORE: https://lnkd.in/erT36fgm

Congratulations to Pappas portfolio company Tune Therapeutics on their approval to initiate their Phase 1b trial!

Congratulations to Pappas Capital portfolio company Enlaza Therapeutics on being named to C&EN's prestigious list of Top 10 Startups to Watch!

Dr. Ernest Mario June 12, 1938 – October 20, 2024 Pappas Capital is deeply saddened to announce the passing of Dr. Ernest “Ernie” Mario, Senior Venture Partner and one of the founders of Pappas’ venture capital business. Ernie joined Pappas Capital’s Scientific Advisory Board in 2002 and became a Senior Venture Partner in 2011. He helped to build Pappas Capital into a leading life science venture capital firm and was a friend and mentor to the entire Pappas team. His work at Glaxo and Duke University, as well as his leadership roles with numerous North Carolina-based life science companies had a significant impact on the growth and development of the state’s life science ecosystem. Ernie was a leader of leaders. He mentored research, development and commercial executives around the world. His impact on patients was profound, bringing forward numerous first and best in class medicines and building organizations to support their growth and development. His focus on academic science at Duke University and Rutgers University is notable and helped ensure their leadership as research intensive organizations. ? Ernie built his life around helping people and his legacy will be the mentoring that he provided to family, friends, and colleagues. He had a unique way of inspiring one to feel great and be eager to do more. His leadership and counsel will be greatly missed.? https://lnkd.in/e44MZ7QG

Congratulations to Pappas portfolio company Aura Biosciences on their positive Phase 1 data!

Art Pappas will be speaking on a panel at #BioFuture2024! Join the discussion on the latest topics shaping the future of #healthcare alongside industry leaders and trailblazing companies. Register at www.BioFuture.com!

Congratulations to Kathleen Sereda Glaub on her appointment to CEO of Pappas portfolio company CuraSen Therapeutics, Inc.! https://lnkd.in/e-33pPna

We are excited to announce that Joshua Grass has been appointed Chairperson of Glycomine’s Board of Directors. We welcome Josh at this pivotal point in our company’s growth as we continue to build the company, advance our lead drug candidate GLM101 in clinical trials as a disease-modifying treatment for PMM2-CDG, and expand our pipeline of therapies for orphan diseases. We would like to sincerely thank Christopher M. Starr for his vision and leadership as BOD chairperson in building Glycomine to this stage and driving GLM101 from a discovery-stage program to a promising late-stage drug candidate, and we look forward to his continued support as a scientific and clinical advisor. Read the release for more: https://lnkd.in/ghYf8SB5 #RareDisease #RareDiseases #PMM2CDG #clinicaltrials